Explore more
Eli Lilly, Novo Nordisk and Zepbound
Digest more
Top News
Overview
Gov. Mike Braun visited Lebanon Tuesday to help break ground for the $4.5 billion Eli Lilly Medicine Foundry in Lebanon. The foundry is the first research and development site of its kind in the world and will combine research,
Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, predicted that though Trump had spared the industry with tariffs, that wouldn't last much longer.
The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult diseases.
Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the workforce-talent pipeline.
Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to-earnings-to-growth (PEG) ratio of 0.4. PEGs below 1 are generally considered undervalued, so on that basis, the stock is very inexpensive.
Eli Lilly and Purdue University expand their partnership with a $250 million investment to advance pharmaceutical innovation and workforce development.
The new research and development site will combine research, process development and clinical trial manufacturing capabilities into one plant.
Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, co-founder Patrick Hsu, Ph.D., told Fierce Biotech. | Stylus Medicine is unsheathing,
Feedback